biotech

CEO Interview

CytoDyn, Inc. (OTC: CYDY) “Game Changer” HIV treatment nears commercialization (plus high-potential cancer drug pipeline)

May 10, 2019 admin Comments Off on CytoDyn, Inc. (OTC: CYDY) “Game Changer” HIV treatment nears commercialization (plus high-potential cancer drug pipeline)

            CytoDyn Inc. (OTC: CYDY) CEO Interview with Nader Pourhassan, Ph.D, providing an update on the company’s drug development pipeline targeting HIV and cancers, based on CytoDyn’s Leronlimab/PRO 140 platform. […]

Healthcare

CytoDyn (OTC: CYDY) Reaches Historical Milestone, Submits First of Three Sections of BLA to FDA for Leronlimab (PRO 140) as a Combination Therapy for HIV

March 21, 2019 admin Comments Off on CytoDyn (OTC: CYDY) Reaches Historical Milestone, Submits First of Three Sections of BLA to FDA for Leronlimab (PRO 140) as a Combination Therapy for HIV

FDA Previously Granted Rolling Review for BLA VANCOUVER, Washington, Mar 18, 2019 – CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”) a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential […]

CEO Interview

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) Creating “blockbuster” potential drugs, from deuterium chemistry tech

March 14, 2019 admin Comments Off on Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) Creating “blockbuster” potential drugs, from deuterium chemistry tech

                  Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) Interview with Roger Tung, CEO discussing the company’s deuterium chemistry platform for creating new drugs which have superior properties—including enhanced clinical safety, tolerability […]

Healthcare

CytoDyn (OTC: CYDY)Reports Significant Reduction in Breast Cancer Tumor Metastasis in Preclinical Study and Requests FDA Fast Track Designation for Leronlimab (PRO 140) in Metastatic-Triple Negative Breast Cancer (mTNBC)

March 12, 2019 admin Comments Off on CytoDyn (OTC: CYDY)Reports Significant Reduction in Breast Cancer Tumor Metastasis in Preclinical Study and Requests FDA Fast Track Designation for Leronlimab (PRO 140) in Metastatic-Triple Negative Breast Cancer (mTNBC)

VANCOUVER, Washington, March 11, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”) a late stage biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced that leronlimab (PRO 140), […]

Healthcare

FDA Grants Rolling Review for CytoDyn’s (OTC: CYDY) Planned BLA for Investigational HIV Therapy Leronlimab (PRO 140)

March 7, 2019 admin Comments Off on FDA Grants Rolling Review for CytoDyn’s (OTC: CYDY) Planned BLA for Investigational HIV Therapy Leronlimab (PRO 140)

VANCOUVER, Washington, March 04, 2019 — CytoDyn Inc. (otc.qb:CYDY), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that the FDA has reviewed […]

Healthcare

CytoDyn (OTC: CYDY) to Present New Data from Study of Investigational HIV Therapy Leronlimab (PRO 140), a Long-Acting, Single-Agent Maintenance Therapy at CROI 2019

February 28, 2019 admin Comments Off on CytoDyn (OTC: CYDY) to Present New Data from Study of Investigational HIV Therapy Leronlimab (PRO 140), a Long-Acting, Single-Agent Maintenance Therapy at CROI 2019

VANCOUVER, Washington, Feb. 27, 2019 — CytoDyn Inc. (OTC.QB: CYDY), a late stage biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced that data from its study of leronlimab […]

Healthcare

CytoDyn’s (OTC: CYDY) Leronlimab (PRO 140) reduces by more than 98% human breast cancer metastasis in mouse xenografts for over 6 weeks

February 20, 2019 admin Comments Off on CytoDyn’s (OTC: CYDY) Leronlimab (PRO 140) reduces by more than 98% human breast cancer metastasis in mouse xenografts for over 6 weeks

Based on strong results in its pre-clinical animal study, CytoDyn files for Orphan Drug Designation for Triple-Negative Breast Cancer VANCOUVER, Washington, Feb 20, 2019 – CytoDyn Inc. (otc.qb:CYDY), a biotechnology company developing a novel humanized […]

Healthcare

CytoDyn (OTC: CYDY) Announces Productive Conference Call with FDA Regarding First BLA Submission for Leronlimab (PRO 140) Combination Therapy at 700 mg Dose

February 7, 2019 admin Comments Off on CytoDyn (OTC: CYDY) Announces Productive Conference Call with FDA Regarding First BLA Submission for Leronlimab (PRO 140) Combination Therapy at 700 mg Dose

VANCOUVER, Washington, Feb 01, 2019 — Successful interim results in the 700 mg monotherapy arm prompted the FDA to allow CytoDyn to switch all remaining combination therapy patients from CD02-Extension study from 350 mg to […]